Cinti S, Coffey M, Sullivan A, Armstrong W, Kazanjian P; Conference on Retroviruses and Opportunistic Infections.
Program Abstr 6th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 6th 1999 Chic Ill. 1999 Jan 31-Feb 4; 6th: 150 (abstract no. 442).
University of Michigan Medical Center, Ann Arbor.
We have previously shown that neutrophils isolated from AIDS patients demonstrate improved growth inhibition of M. avium when incubated with exogenous GM-CSF. In this study, 30 AIDS patients without M. avium infection were randomized to receive treatment with azithromycin (1200 mg), GM-CSF (250 micrograms/m2/Day X 5 days), or both agents. The M. avium killing capacity of neutrophils and monocytes harvested from each patient before intervention, during (day 4) and after therapy (day 8) was assessed. The mean viral load change in the groups receiving GM-CSF was + 0.14 log of viral RNA. For neutrophils and monocytes respectively, there was no significant reduction in M. avium growth after therapy for patients treated with GM-CSF (P=.96 and P=.31). Bone pain, myalgia, presyncope, or fever, occurred in 55% of patients receiving GM-CSF; symptoms improved with dose reduction in 15% but required discontinuation of the agent in another 10%. Thus, the GM-CSF regimen used in this study did not affect virus load, caused adverse reactions, and did not improve the M. avium killing capacity of neutrophils and monocytes. Future studies are indicated using an incremental GM-CSF regimen beginning with a lower initial dose for a longer duration.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Azithromycin
- Granulocyte Macrophage Colony-Stimulating Factors, Recombinant
- Granulocyte-Macrophage Colony-Stimulating Factor
- Homicide
- Humans
- Monocytes
- Mycobacterium avium
- Mycobacterium avium Complex
- Mycobacterium avium-intracellulare Infection
- Neutrophils
Other ID:
UI: 102195211
From Meeting Abstracts